{"filing":{"accession_number":"0001819790-26-000066","cik":"0001819790","ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-04","primary_document":"tars-20260904.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000066/tars-20260904.htm"},"events":[{"id":32637,"run_id":29999,"accession_number":"0001819790-26-000066","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, pursuant to a merger agreement dated July 31, 2026. The transaction involved $270 million in up-front cash consideration, 2.9 million shares of common stock, and up to $350 million in milestone payments plus revenue sharing on future sales of gildeuretinol (ALK-001), a Phase 3 investigational medicine for Stargardt disease with Breakthrough Therapy and Orphan Drug designations, materially expanding Tarsus' pipeline.","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35854,"accession_number":"0001819790-26-000066","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses completion of Tarsus Pharmaceuticals' acquisition of Alkeus Pharmaceuticals on September 4, 2026, pursuant to a merger agreement dated July 31, 2026. The transaction involved $270 million in up-front cash consideration, 2.9 million shares of common stock, and up to $350 million in milestone payments plus revenue sharing on future sales of gildeuretinol (ALK-001). This is a material acquisition of a late-stage clinical-stage asset (Phase 3 program for Stargardt disease) that expands Tarsus' pipeline and represents a significant capital deployment and strategic transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:09:15.042473+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35855,"accession_number":"0001819790-26-000066","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses completion of Tarsus Pharmaceuticals' acquisition of Alkeus Pharmaceuticals, announced on August 6, 2026 and closed on September 4, 2026. The acquisition adds ALK-001 (gildeuretinol), a Phase 3 investigational medicine for Stargardt disease with Breakthrough Therapy and Orphan Drug designations, representing a material expansion of Tarsus' pipeline and strategic positioning in eye care. This is a completed material acquisition that would materially affect a reasonable investor's assessment of the company's assets, pipeline, and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:09:15.042473+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35854,"accession_number":"0001819790-26-000066","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses completion of Tarsus Pharmaceuticals' acquisition of Alkeus Pharmaceuticals on September 4, 2026, pursuant to a merger agreement dated July 31, 2026. The transaction involved $270 million in up-front cash consideration, 2.9 million shares of common stock, and up to $350 million in milestone payments plus revenue sharing on future sales of gildeuretinol (ALK-001). This is a material acquisition of a late-stage clinical-stage asset (Phase 3 program for Stargardt disease) that expands Tarsus' pipeline and represents a significant capital deployment and strategic transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:09:15.042473+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-09-10"},{"id":35855,"accession_number":"0001819790-26-000066","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses completion of Tarsus Pharmaceuticals' acquisition of Alkeus Pharmaceuticals, announced on August 6, 2026 and closed on September 4, 2026. The acquisition adds ALK-001 (gildeuretinol), a Phase 3 investigational medicine for Stargardt disease with Breakthrough Therapy and Orphan Drug designations, representing a material expansion of Tarsus' pipeline and strategic positioning in eye care. This is a completed material acquisition that would materially affect a reasonable investor's assessment of the company's assets, pipeline, and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:09:15.042473+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-09-10"}]}